These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32984034)

  • 41. Cabozantinib in the treatment of hepatocellular carcinoma.
    B Peters ML; Miksad RA
    Future Oncol; 2017 Sep; 13(22):1915-1929. PubMed ID: 28703624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New molecular insights into osteosarcoma targeted therapy.
    Yang J; Zhang W
    Curr Opin Oncol; 2013 Jul; 25(4):398-406. PubMed ID: 23666471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance.
    Dolan M; Mastri M; Tracz A; Christensen JG; Chatta G; Ebos JML
    PLoS One; 2019; 14(8):e0220101. PubMed ID: 31369645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors.
    Cohen MS; Hussain HB; Moley JF
    Surgery; 2002 Dec; 132(6):960-6; discussion 966-7. PubMed ID: 12490842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
    Wang X; Goldstein D; Crowe PJ; Yang JL
    Onco Targets Ther; 2016; 9():5461-73. PubMed ID: 27660463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
    Osanto S; van der Hulle T
    Ther Adv Urol; 2018 Mar; 10(3):109-123. PubMed ID: 29662541
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene.
    Mendes Oliveira D; Grillone K; Mignogna C; De Falco V; Laudanna C; Biamonte F; Locane R; Corcione F; Fabozzi M; Sacco R; Viglietto G; Malanga D; Rizzuto A
    J Exp Clin Cancer Res; 2018 Apr; 37(1):84. PubMed ID: 29665843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
    Kim DY
    Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Developing target therapy against oncogenic tyrosine kinase in myeloid maliganacies.
    Naoe T
    Curr Pharm Biotechnol; 2006 Oct; 7(5):331-7. PubMed ID: 17076649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T; Liang Y; Zhu V; Ou SI
    Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New targets and therapies for gastrointestinal stromal tumors.
    Wozniak A; Gebreyohannes YK; Debiec-Rychter M; Schöffski P
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1117-1129. PubMed ID: 29110548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.
    O'Flanagan CH; O'Shea S; Lyons A; Fogarty FM; McCabe N; Kennedy RD; O'Connor R
    Oncotarget; 2016 Aug; 7(35):56826-56841. PubMed ID: 27472395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.
    Lai Y; Zhao Z; Zeng T; Liang X; Chen D; Duan X; Zeng G; Wu W
    Cancer Cell Int; 2018; 18():31. PubMed ID: 29527128
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report.
    Furuto Y; Hashimoto H; Namikawa A; Outi H; Takahashi H; Horiuti H; Honda K; Shibuya Y
    BMC Nephrol; 2018 Oct; 19(1):273. PubMed ID: 30340546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses.
    Takeuchi Y; Fujino Y; Fukushima K; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
    J Vet Pharmacol Ther; 2012 Feb; 35(1):97-104. PubMed ID: 21480930
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway.
    Ma W; Kang Y; Ning L; Tan J; Wang H; Ying Y
    Exp Ther Med; 2017 Oct; 14(4):2853-2862. PubMed ID: 28912847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted therapies in thyroid cancer: an extensive review of the literature.
    Bikas A; Vachhani S; Jensen K; Vasko V; Burman KD
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1299-1313. PubMed ID: 27367142
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.